Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions

Table 2

Results of randomized trials on immediate adjuvant RT.

Trial	SWOG 8794	EORTC 22911	ARO 96-02
Overall survival	HR: 0.72; (95% CI 0.55–0.96),; 𝑃=0.023	HR: 1.09; (98% CI 0.67–1.79),; 𝑃=0.68	Not reported
bNED	HR: 0.43; (95% CI 0.31–0.58),; 𝑃<0.001	HR: 0.48; (98% CI 0.37–0.62),; 𝑃<0.0001	HR: 0.53; (95% CI 0.37–0.79),; 𝑃=0.0015
Metastasis-free survival	HR: 0.71; (95% CI 0.54–0.94),; 𝑃=0.016	Not reported	98% versus 95.1 % (n.s.)
Clinical progression-free survival	HR: 0.62; (95% CI 0.46–0.82),; 𝑃=0.001	HR: 0.61; (98% CI 0.43–0.87),; 𝑃=0.0009	Not reported
Time to initiation of hormonal therapy	HR: 0.45; (95% CI 0.29–0.68),; 𝑃<0.001	Not reported	Not reported
Overall toxicity	23.8% versus 11.9%,; 𝑃=0.002	4.2% versus 2.6%; (Grade 3; 𝑃=0.07)	21.9% versus 3.7%,; 𝑃<0.0001
Rectal toxicity	3.3% versus 0%,; 𝑃=0.02	Not reported	1.4% versus 0%
Urinary stricture	17.8% versus 9.5%,; 𝑃=0.02	Not reported	Not reported
Total urinary incontinence	6.5% versus 2.8%,; 𝑃=0.11	Not reported	Not reported

HR: hazard ratio; CI: confidence interval; n.s.: not significant.